Serina Therapeutics (SER) said Tuesday that it raised $5 million in financing from shareholders, which will be utilized to support the development of POZ-apomorphine to treat Advanced Parkinson's disease.
The phase 1 clinical trial of the candidate is expected to commence in Q4, the company said.
The company raised the financing by issuing 965,250 shares of convertible preferred stock at $5.18 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.